Cited by 497Genetic Neurodegenerative DiseasesUbiquitin and proteasome pathwaysLysosomal Storage Disorders Research

The DOI matches its Crossref record; 28 of the 28 references it cites were found in a registry or an index.

Global changes to the ubiquitin system in Huntington's disease

Bennett, Eric J., Shaler, Thomas A., Woodman, Ben, Ryu, Kwon-Yul, Zaitseva, Tatiana S., Becker, Christopher H., Bates, Gillian P., Schulman, Howard, Kopito, Ron R.·2007·Nature

DOI 10.1038/nature06022

Open this paper in CoChat — free account

Abstract

Huntington's disease (HD) is a dominantly inherited neurodegenerative disorder caused by expansion of CAG triplet repeats in the huntingtin (HTT) gene (also called HD) and characterized by accumulation of aggregated fragments of polyglutamine-expanded HTT protein in affected neurons. Abnormal enrichment of HD inclusion bodies with ubiquitin, a diagnostic characteristic of HD and many other neurodegenerative disorders including Alzheimer's and Parkinson's diseases, has suggested that dysfunction in ubiquitin metabolism may contribute to the pathogenesis of these diseases. Because modification of proteins with polyubiquitin chains regulates many essential cellular processes including protein degradation, cell cycle, transcription, DNA repair and membrane trafficking, disrupted ubiquitin signalling is likely to have broad consequences for neuronal function and survival. Although ubiquitin-dependent protein degradation is impaired in cell-culture models of HD and of other neurodegenerative diseases, it has not been possible to evaluate the function of the ubiquitin-proteasome system (UPS) in HD patients or in animal models of the disease, and a functional role for UPS impairment in neurodegenerative disease pathogenesis remains controversial. Here we exploit a mass-spectrometry-based method to quantify polyubiquitin chains and demonstrate that the abundance of these chains is a faithful endogenous biomarker of UPS function. Lys 48-linked polyubiquitin chains accumulate early in pathogenesis in brains from the R6/2 transgenic mouse model of HD, from a knock-in model of HD and from human HD patients, establishing that UPS dysfunction is a consistent feature of HD pathology. Lys 63- and Lys 11-linked polyubiquitin chains, which are not typically associated with proteasomal targeting, also accumulate in the R6/2 mouse brain. Thus, HD is linked to global changes in the ubiquitin system to a much greater extent than previously recognized.

Integrity signals

Registry

Crossref · 10.1038/nature06022

Cites

28 of 28 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

A novel gene containing a trinucleotide repeat that is expanded and unstable on Huntington's disease chromosomes
MACDONALD, M. (1993) · Cell · doi:10.1016/0092-8674(93)90585-e · Cited by 8,366
Exon 1 of the HD gene with an expanded CAG repeat is sufficient to cause a progressive neurological phenotype in transgenic mice
Mangiarini, L., Sathasivam, K., Seller, M., Cozens, B., Harper, A., Hetherington, C., Lawton, M., Trottier, Y., Lehrach, H., Davies, S. W., et al. (1996) · Cell · doi:10.1016/s0092-8674(00)81369-0 · Cited by 3,073
Self-citation
Aggregation of Huntingtin in Neuronal Intranuclear Inclusions and Dystrophic Neurites in Brain
DiFiglia, M., Sapp, E., Chase, K. O., Davies, S. W., Bates, G. P., Vonsattel, J. P., & Aronin, N. (1997) · Science · doi:10.1126/science.277.5334.1990 · Cited by 2,439
Self-citation
Impairment of the Ubiquitin-Proteasome System by Protein Aggregation
Bence, N., Sampat, R. M., & Kopito, R. R. (2001) · Science · doi:10.1126/science.292.5521.1552 · Cited by 2,209
Self-citation
Polyubiquitin chains: polymeric protein signals
Pickart, C. M., & Fushman, D. (2004) · Current Opinion in Chemical Biology · doi:10.1016/j.cbpa.2004.09.009 · Cited by 1,075
Neurological abnormalities in a knock-in mouse model of Huntington's disease
Lin, C. (2001) · Human Molecular Genetics · doi:10.1093/hmg/10.2.137 · Cited by 592
Parkin Protects against the Toxicity Associated with Mutant α-Synuclein
Petrucelli, L., O’Farrell, C., Lockhart, P. J., Baptista, M. J., Kehoe, K. J., Vink, L., Choi, P., Wolozin, B. L., Farrer, M. J., Hardy, J., et al. (2002) · Neuron · doi:10.1016/s0896-6273(02)01125-x · Cited by 561
Ubiquitin is a common factor in intermediate filament inclusion bodies of diverse type in man, including those of Parkinson's disease, Pick's disease, and Alzheimer's disease, as well as Rosenthal fibres in cerebellar astrocytomas, cytoplasmic bodies in muscle, and mallory bodies in alcoholic liver disease
Lowe, J., Blanchard, A., Morrell, K., Lennox, G., Reynolds, L., Billett, M., Landon, M., & Mayer, R. J. (1988) · The Journal of Pathology · doi:10.1002/path.1711550105 · Cited by 539
Global Impairment of the Ubiquitin-Proteasome System by Nuclear or Cytoplasmic Protein Aggregates Precedes Inclusion Body Formation
Bennett, E. J., Bence, N., Rajadas, J., & Kopito, R. R. (2005) · Molecular Cell · doi:10.1016/j.molcel.2004.12.021 · Cited by 511
Self-citation
Altered proteasomal function due to the expression of polyglutamine-expanded truncated N-terminal huntingtin induces apoptosis by caspase activation through mitochondrial cytochrome c release
Jana, N. R. (2001) · Human Molecular Genetics · doi:10.1093/hmg/10.10.1049 · Cited by 453

Flagged first, then by citations

Show all 28 references

Sorted by citations

Items 201–300 of 497

Changes in BiP availability reveal hypersensitivity to acute endoplasmic reticulum stress in cells expressing mutant huntingtin
Lajoie, P., & Snapp, E. L. (2011) · Journal of Cell Science · doi:10.1242/jcs.087510 · Cited by 50
Huntington’s disease and striatal signaling
Roze, E. F. (2011) · Frontiers in Neuroanatomy · doi:10.3389/fnana.2011.00055 · Cited by 56
Protein stability and aggregation in Parkinson's disease
Robinson, P. A. (2008) · Biochemical Journal · doi:10.1042/bj20080295 · Cited by 50
Broad Spectrum of Hepatocyte Inclusions in Humans, Animals, and Experimental Models
Strnad, P., Nuraldeen, R., Güldiken, N., Hartmann, D., Mahajan, V., Denk, H., & Haybaeck, J. (2013) · Comprehensive physiology · doi:10.1002/cphy.c120032 · Cited by 52
Polyglutamine Expanded Huntingtin Dramatically Alters the Genome-Wide Binding of HSF1
Riva, L., Koeva, M., Yildirim, F., Pirhaji, L., Dinesh, D., Mazor, T., Duennwald, M. L., & Fraenkel, E. (2012) · Journal of Huntington s Disease · doi:10.3233/jhd-2012-120020 · Cited by 49
The role of amyloidogenic protein oligomerization in neurodegenerative disease
Lotz, G. P., & Legleiter, J. A. (2013) · Journal of Molecular Medicine · doi:10.1007/s00109-013-1025-1 · Cited by 49
Intracellular degradation of misfolded proteins in polyglutamine neurodegenerative diseases
Li, X., He, L., & Li, X. (2008) · Brain Research Reviews · doi:10.1016/j.brainresrev.2008.08.003 · Cited by 48
Small molecule modulator of protein disulfide isomerase attenuates mutant huntingtin toxicity and inhibits endoplasmic reticulum stress in a mouse model of Huntington’s disease
Zhou, X., Li, G., Kaplan, A. R., Gaschler, M. M., Zhang, X., Hou, Z., Jiang, M., Piantedosi, R., Cremers, S., Stockwell, B. R., et al. (2018) · Human Molecular Genetics · doi:10.1093/hmg/ddy061 · Cited by 48
DNA repair and neurological disease: From molecular understanding to the development of diagnostics and model organisms
Abugable, A. A., Morris, J. L. M., Palminha, N. M., Zaksauskaite, R., Ray, S., & El‐Khamisy, S. F. (2019) · DNA repair · doi:10.1016/j.dnarep.2019.102669 · Cited by 53
Cellular protein quality control and the evolution of aggregates in spinocerebellar ataxia type 3 (SCA3)
Seidel, K., Meister, M., Dugbartey, G. J., Zijlstra, M. P., Vinet, J., Brunt, E. R. P., van Leeuwen, F. W., Rüb, U., Kampinga, H. H., & den Dunnen, W. F. A. (2011) · Neuropathology and Applied Neurobiology · doi:10.1111/j.1365-2990.2011.01220.x · Cited by 49
Suppression of polyglutamine‐induced cytotoxicity in Saccharomyces cerevisiae by enhancement of mitochondrial biogenesis
Ocampo, A., Zambrano, A., & Barrientos, A. (2009) · The FASEB Journal · doi:10.1096/fj.09-148601 · Cited by 47
Ubiquitinated Proteome: Ready for Global?
Shi, Y., Xu, P., & Qin, J. (2011) · Molecular & Cellular Proteomics · doi:10.1074/mcp.r110.006882 · Cited by 48
NAD+ salvage pathway proteins suppress proteotoxicity in yeast models of neurodegeneration by promoting the clearance of misfolded/oligomerized proteins
Ocampo, A., Liu, J., & Barrientos, A. (2013) · Human Molecular Genetics · doi:10.1093/hmg/ddt016 · Cited by 47
Ubiquitylome analysis reveals a central role for the ubiquitin-proteasome system in plant innate immunity
Ma, X., Zhang, C., ‍Kim, D. Y., Huang, Y., Chatt, E. C., He, P., Vierstra, R. D., & Shan, L. (2021) · PLANT PHYSIOLOGY · doi:10.1093/plphys/kiab011 · Cited by 47
Schwann cell autophagy induced by SAHA, 17-AAG, or clonazepam can reduce bortezomib-induced peripheral neuropathy
Watanabe, T., Nagase, K., Chosa, M., & Tobinai, K. (2010) · British Journal of Cancer · doi:10.1038/sj.bjc.6605954 · Cited by 47
Suppression of Mutant Huntingtin Aggregate Formation by Cdk5/p35 through the Effect on Microtubule Stability
Kaminosono, S., Saito, T., Oyama, F., Ohshima, T., Asada, A., Nagai, Y., Nukina, N., & Hisanaga, S.-I. (2008) · Journal of Neuroscience · doi:10.1523/jneurosci.0973-08.2008 · Cited by 48
Cost‐effectiveness of hydroxyurea in reducing the frequency of pain episodes and hospitalization in pediatric sickle cell disease
Stallworth, J. R., Jerrell, J. M., & Tripathi, A. (2010) · American Journal of Hematology · doi:10.1002/ajh.21772 · Cited by 47
Proteasomes Cleave at Multiple Sites within Polyglutamine Tracts
Pratt, G. W., & Rechsteiner, M. (2008) · Journal of Biological Chemistry · doi:10.1074/jbc.m709347200 · Cited by 46
Ubiquitin‐binding domains: Mechanisms of ubiquitin recognition and use as tools to investigate ubiquitin‐modified proteomes
Scott, D., Oldham, N. J., Strachan, J., Searle, M. S., & Layfield, R. (2014) · PROTEOMICS · doi:10.1002/pmic.201400341 · Cited by 49
Epigenetic Treatment of Neurological Disease
Gray, S. G. (2011) · Epigenomics · doi:10.2217/epi.11.67 · Cited by 45
PLAA Mutations Cause a Lethal Infantile Epileptic Encephalopathy by Disrupting Ubiquitin-Mediated Endolysosomal Degradation of Synaptic Proteins
Hall, E. A., Nahorski, M. S., Murray, L. M., Shaheen, R., Perkins, E., Dissanayake, K. N., Kristaryanto, Y., Jones, R. A., Vogt, J., Rivagorda, M., et al. (2017) · The American Journal of Human Genetics · doi:10.1016/j.ajhg.2017.03.008 · Cited by 45
The Role of Adenosine Tone and Adenosine Receptors in Huntington's Disease
Blum, D. L., Chern, Y., Domenici, M. R., Buée, L., Lin, C., Rea, W. P., Ferré, S., & Popoli, P. (2018) · Journal of Caffeine and Adenosine Research · doi:10.1089/caff.2018.0006 · Cited by 48
Proteomics: From Technology Developments to Biological Applications
Abu‐Farha, M., Elisma, F., Zhou, H., Tian, R., Zhou, H., Asmer, M. S., & Figeys, D. (2009) · Analytical Chemistry · doi:10.1021/ac900735j · Cited by 46
Top-Down Proteomics with Mass Spectrometry Imaging: A Pilot Study towards Discovery of Biomarkers for Neurodevelopmental Disorders
Ye, H., Mandal, R., Catherman, A. D., Thomas, P. M., Kelleher, N. L., Ikonomidou, C., & Li, L. (2014) · PLoS ONE · doi:10.1371/journal.pone.0092831 · Cited by 45
Adenosine Receptors and Huntington's Disease
Lee, C.-F., & Chern, Y. (2014) · International review of neurobiology · doi:10.1016/b978-0-12-801022-8.00010-6 · Cited by 44
Selective autophagy as the basis of autophagy-based degraders
Takahashi, D., & Arimoto, H. (2021) · Cell chemical biology · doi:10.1016/j.chembiol.2021.05.006 · Cited by 44
Neuroprotection for Huntington’s Disease: Ready, Set, Slow
Hersch, S. M., & Rosas, H. D. (2008) · Neurotherapeutics · doi:10.1016/j.nurt.2008.01.003 · Cited by 44
Anaphase-Promoting Complex/Cyclosome Participates in the Acute Response to Protein-Damaging Stress
Ahlskog, J. K., Björk, J., Elsing, A. N., Aspelin, C., Kallio, M. J., Roos‐Mattjus, P., & Sistonen, L. (2010) · Molecular and Cellular Biology · doi:10.1128/mcb.01506-09 · Cited by 44
Large-Scale Screen for Modifiers of Ataxin-3-Derived Polyglutamine-Induced Toxicity in Drosophila
Voßfeldt, H., Butzlaff, M., Prüßing, K., Chárthaigh, R.-A. N., Karsten, P., Lankes, A., Hamm, S., Simons, M., Adryan, B., Schulz, J. B., et al. (2012) · PLoS ONE · doi:10.1371/journal.pone.0047452 · Cited by 43
Huntington's Disease and its therapeutic target genes: a global functional profile based on the HD Research Crossroads database
Kalathur, R. K. R., Hernández‐Prieto, M. A., & Futschik, M. E. (2012) · BMC Neurology · doi:10.1186/1471-2377-12-47 · Cited by 46
Neural and mesenchymal stem cells in animal models of Huntington’s disease: past experiences and future challenges
Kerkis, I., Haddad, M. S., Valverde, C. W., & Glosman, S. (2015) · Stem Cell Research & Therapy · doi:10.1186/s13287-015-0248-1 · Cited by 43
Targeting Ubiquitin-Proteasome Pathway by Natural Products: Novel Therapeutic Strategy for Treatment of Neurodegenerative Diseases
Momtaz, S., Memariani, Z., El‐Senduny, F. F., Sanadgol, N., Golab, F., Katebi, M., Abdolghaffari, A. H., Farzaei, M. H., & Abdollahi, M. R. (2020) · Frontiers in Physiology · doi:10.3389/fphys.2020.00361 · Cited by 46
Proteasome and oxidative phoshorylation changes may explain why aging is a risk factor for neurodegenerative disorders
Zabel, C., Nguyen, H. P., Hin, S. C., Hartl, D., Mao, L., & Klose, J. (2010) · Journal of Proteomics · doi:10.1016/j.jprot.2010.08.008 · Cited by 44
How the binding and degrading capabilities of insulin degrading enzyme are affected by ubiquitin
Grasso, G., Rizzarelli, E., & Spoto, G. (2008) · Biochimica et Biophysica Acta (BBA) - Proteins and Proteomics · doi:10.1016/j.bbapap.2008.04.011 · Cited by 43
Misfolded PrP and a novel mechanism of proteasome inhibition
André, R., & Tabrizi, S. J. (2012) · Prion · doi:10.4161/pri.6.1.18272 · Cited by 42
Modulation of K11-Linkage Formation by Variable Loop Residues within UbcH5A
Bosanac, I., Phu, L., Pan, B., Zilberleyb, I., Maurer, B., Dixit, V. M., Hymowitz, S. G., & Kirkpatrick, D. S. (2011) · Journal of Molecular Biology · doi:10.1016/j.jmb.2011.03.011 · Cited by 42
Atypical ubiquitination by E3 ligase WWP1 inhibits the proteasome-mediated degradation of mutant huntingtin
Li, L., Jin, Z., Tan, H., Xu, Q., Peng, T., & He, L. (2016) · Brain Research · doi:10.1016/j.brainres.2016.03.027 · Cited by 44
ER Stress and Neurodegenerative Disease: A Cause or Effect Relationship?
Cabral‐Miranda, F., & Hetz, C. A. (2017) · Current topics in microbiology and immunology · doi:10.1007/82_2017_52 · Cited by 46
Expression of Regulatory Proteins in Choroid Plexus Changes in Early Stages of Alzheimer Disease
Krzyzanowska, A., García-Consuegra, I., Pascual, C., Antequera, D., Ferrer, I., & Carro, E. (2015) · Journal of Neuropathology & Experimental Neurology · doi:10.1097/nen.0000000000000181 · Cited by 42
Immunoreactivity to Lys63-linked polyubiquitin is a feature of neurodegeneration
Paine, S., Bedford, L., Thorpe, J. R., Mayer, R. J., Cavey, J. R., Bajaj, N., Sheppard, P. W., Lowe, J., & Layfield, R. (2009) · Neuroscience Letters · doi:10.1016/j.neulet.2009.05.074 · Cited by 41
Bifunctional Apoptosis Regulator (BAR), an Endoplasmic Reticulum (ER)-associated E3 Ubiquitin Ligase, Modulates BI-1 Protein Stability and Function in ER Stress
Rong, J., Chen, L., Toth, J. I., Tcherpakov, M., Petroski, M. D., & Reed, J. C. (2010) · Journal of Biological Chemistry · doi:10.1074/jbc.m110.175232 · Cited by 44
The Proteasome in Health and Disease
Jankowska, E., Stoj, J., Karpowicz, P., Osmulski, P. A., & Gaczynska, M. E. (2012) · Current Pharmaceutical Design · doi:10.2174/138161281906141012124358 · Cited by 43
Dynamic recruitment of ubiquitin to mutant huntingtin inclusion bodies
Juenemann, K., Jansen, A. H. P., van Riel, L. A. M. J. G., Merkx, R., Mulder, M. P. C., An, H., Statsyuk, A. V., Kirstein, J., Ovaa, H., & Reits, E. A. (2018) · Scientific Reports · doi:10.1038/s41598-018-19538-0 · Cited by 43
Small molecule drug discovery for Huntington's Disease
Fecke, W., Gianfriddo, M., Gaviraghi, G., Terstappen, G. C., & Heitz, F. (2009) · Drug Discovery Today · doi:10.1016/j.drudis.2009.02.006 · Cited by 43
Evaluation of proteomic strategies for analyzing ubiquitinated proteins
Peng, J. M. (2008) · BMB Reports · doi:10.5483/bmbrep.2008.41.3.177 · Cited by 40
Ubiquilin-1 Overexpression Increases the Lifespan and Delays Accumulation of Huntingtin Aggregates in the R6/2 Mouse Model of Huntington's Disease
Safren, N., Ayadi, A. E., Chang, L., Terrillion, C. E., Gould, T. D., Boehning, D. F., & Monteiro, M. J. (2014) · PLoS ONE · doi:10.1371/journal.pone.0087513 · Cited by 40
Proteomic techniques to probe the ubiquitin landscape
Beaudette, P., Popp, O., & Dittmar, G. (2015) · PROTEOMICS · doi:10.1002/pmic.201500290 · Cited by 43
Azadiradione Restores Protein Quality Control and Ameliorates the Disease Pathogenesis in a Mouse Model of Huntington’s Disease
Singh, B. K., Vatsa, N., Nelson, V. K., Kumar, V., Kumar, R., Mandal, S. C., Pal, M., & Jana, N. R. (2018) · Molecular Neurobiology · doi:10.1007/s12035-017-0853-3 · Cited by 40
Conformation Sensors that Distinguish Monomeric Proteins from Oligomers in Live Cells
Ramdzan, Y. M., Nisbet, R. M., Miller, J. M. L., Finkbeiner, S. M., Hill, A. F., & Hatters, D. M. (2010) · Chemistry & Biology · doi:10.1016/j.chembiol.2010.03.011 · Cited by 40
Rosiglitazone activation of PPARγ-dependent signaling is neuroprotective in mutant huntingtin expressing cells
Chiang, M., Cheng, Y., Nicol, C. J. B., Lin, K., Yen, C., Chen, S., & Huang, R. (2015) · Experimental Cell Research · doi:10.1016/j.yexcr.2015.09.005 · Cited by 39
In Vitro Differentiation of Human Neural Progenitor Cells Into Striatal GABAergic Neurons
Lin, L., Yuan, J., Sander, B. O., & Golas, M. M. (2015) · Stem Cells Translational Medicine · doi:10.5966/sctm.2014-0083 · Cited by 41
Targeting Hsp70 facilitated protein quality control for treatment of polyglutamine diseases
Davis, A. K., Pratt, W. B., Lieberman, A. P., & Osawa, Y. (2019) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-019-03302-2 · Cited by 39
Trafficking‐deficient mutant GABRG2 subunit amount may modify epilepsy phenotype
Kang, J., Shen, W., & Macdonald, R. L. (2013) · Annals of Neurology · doi:10.1002/ana.23947 · Cited by 39
Methamphetamine, Neurotransmitters and Neurodevelopment
Čechová, B., & Šlamberová, R. (2021) · Physiological Research · doi:10.33549/physiolres.934821 · Cited by 38
Mouse Models of Polyglutamine Diseases in Therapeutic Approaches: Review and Data Table. Part II
Switonski, P. M., Szlachcic, W. J., Gabka, A., Krzyżosiak, W. J., & Figiel, M. (2012) · Molecular Neurobiology · doi:10.1007/s12035-012-8316-3 · Cited by 38
Protein misfolding specifies recruitment to cytoplasmic inclusion bodies
Bersuker, K., Brandeis, M., & Kopito, R. R. (2016) · The Journal of Cell Biology · doi:10.1083/jcb.201511024 · Cited by 38
Self-citation
Ubiquitin Accumulation on Disease Associated Protein Aggregates Is Correlated with Nuclear Ubiquitin Depletion, Histone De-Ubiquitination and Impaired DNA Damage Response
Yehuda, A. B., Risheq, M., Novoplansky, O., Bersuker, K., Kopito, R. R., Goldberg, M., & Brandeis, M. (2017) · PLoS ONE · doi:10.1371/journal.pone.0169054 · Cited by 39
Self-citation
BAG1 modulates huntingtin toxicity, aggregation, degradation, and subcellular distribution
Sroka, K., Voigt, A., Deeg, S., Reed, J. C., Schulz, J. B., Bähr, M., & Kermer, P. (2009) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2009.06363.x · Cited by 38
Transglutaminase Activation in Neurodegenerative Diseases
Jeitner, T. M., Muma, N. A., Battaile, K. P., & Cooper, A. J. L. (2009) · Future Neurology · doi:10.2217/fnl.09.17 · Cited by 38
Immunohistochemical Analysis of the Ubiquitin Proteasome System and Autophagy Lysosome System Induced After Traumatic Intracranial Injury
Sakai, K., Fukuda, T., & Iwadate, K. (2013) · American Journal of Forensic Medicine & Pathology · doi:10.1097/paf.0000000000000067 · Cited by 37
Use of human stem cells in Huntington disease modeling and translational research
Golas, M. M., & Sander, B. O. (2016) · Experimental Neurology · doi:10.1016/j.expneurol.2016.01.021 · Cited by 37
The regulatory roles of microRNAs toward pathogenesis and treatments in Huntington's disease
Tung, C.-W., Huang, P.-Y., Chan, S. C., Cheng, P., & Yang, S. (2021) · Journal of Biomedical Science · doi:10.1186/s12929-021-00755-1 · Cited by 38
Reduced Levels of Proteasome Products in a Mouse Striatal Cell Model of Huntington’s Disease
Dasgupta, S., Fishman, M. A., Mahallati, H., Castro, L. M., Tashima, A. K., Ferro, E. S., & Fricker, L. D. (2015) · PLoS ONE · doi:10.1371/journal.pone.0145333 · Cited by 37
Modulation of Molecular Chaperones in Huntington’s Disease and Other Polyglutamine Disorders
Reis, S., Pinho, B. R., & Oliveira, J. M. A. (2016) · Molecular Neurobiology · doi:10.1007/s12035-016-0120-z · Cited by 38
Restoration of BDNF, DARPP32, and D2R Expression Following Intravenous Infusion of Human Immature Dental Pulp Stem Cells in Huntington’s Disease 3-NP Rat Model
Wenceslau, C. V., de Souza, D. M., Mambelli-Lisboa, N. C., Ynoue, L. H., Araldi, R. P., da Silva, J. M., Pagani, E., Haddad, M. S., & Kerkis, I. (2022) · Cells · doi:10.3390/cells11101664 · Cited by 36
Animal Models of Polyglutamine Diseases and Therapeutic Approaches
Marsh, J., Lukácsovich, T., & Thompson, L. M. (2008) · Journal of Biological Chemistry · doi:10.1074/jbc.r800065200 · Cited by 37
HDAC Inhibitor Modulation of Proteotoxicity as a Therapeutic Approach in Cancer
McConkey, D. J., White, M. C., & Yan, W. (2012) · Advances in cancer research · doi:10.1016/b978-0-12-394387-3.00004-5 · Cited by 35
Effects of partial suppression of parkin on huntingtin mutant R6/1 mice
Rubio, I., Rodríguez‐Navarro, J. A., Tomás‐Zapico, C., Ruíz, C., Casarejos, M. J., Perucho, J., Gómez, A., Rodal, I., Lucas, J. J., Mena, M. A., et al. (2009) · Brain Research · doi:10.1016/j.brainres.2009.05.039 · Cited by 35
FOXOs modulate proteasome activity in human-induced pluripotent stem cells of Huntington’s disease and their derived neural cells
Liu, Y., Qiao, F., Leiferman, P. C., Ross, A. D., Schlenker, E. H., & Wang, H. (2017) · Human Molecular Genetics · doi:10.1093/hmg/ddx327 · Cited by 35
Ubiquitin turnover and endocytic trafficking in yeast are regulated by Ser57 phosphorylation of ubiquitin
Lee, S., Tumolo, J. M., Ehlinger, A. C., Jernigan, K. K., Qualls, S. J., Hsu, P.-C., McDonald, W. H., Chazin, W., & MacGurn, J. A. (2017) · eLife · doi:10.7554/elife.29176 · Cited by 36
Withaferin A Induces Heat Shock Response and Ameliorates Disease Progression in a Mouse Model of Huntington’s Disease
Joshi, T., Kumar, V., Kaznacheyeva, E. V., & Jana, N. R. (2021) · Molecular Neurobiology · doi:10.1007/s12035-021-02397-8 · Cited by 34
Targeting Histone Deacetylases for the Treatment of Huntington's Disease
Gray, S. G. (2010) · CNS Neuroscience & Therapeutics · doi:10.1111/j.1755-5949.2010.00184.x · Cited by 34
Ku70 Alleviates Neurodegeneration in Drosophila Models of Huntington's Disease
Tamura, T., Sone, M., Iwatsubo, T., Tagawa, K., Wanker, E. E., & Okazawa, H. (2011) · PLoS ONE · doi:10.1371/journal.pone.0027408 · Cited by 34
Inducible mutant huntingtin expression in HN10 cells reproduces Huntington's disease-like neuronal dysfunction
Weiss, A., Roscic, A., & Paganetti, P. (2009) · Molecular Neurodegeneration · doi:10.1186/1750-1326-4-11 · Cited by 34
The neuronal ubiquitin-proteasome system: Murine models and their neurological phenotype
van Tijn, P., Hol, E. M., van Leeuwen, F. W., & Fischer, D. F. (2008) · Progress in Neurobiology · doi:10.1016/j.pneurobio.2008.03.001 · Cited by 35
Direct and/or Indirect Roles for SUMO in Modulating Alpha-Synuclein Toxicity
Vijayakumaran, S., Wong, M. B., Antony, H., & Pountney, D. L. (2015) · Biomolecules · doi:10.3390/biom5031697 · Cited by 34
Fragments of HdhQ150 Mutant Huntingtin Form a Soluble Oligomer Pool That Declines with Aggregate Deposition upon Aging
Marcellin, D., Abramowski, D., Young, D., Richter, J., Weiss, A., Marcel, A., Maassen, J., Kauffmann, M., Bibel, M., Shimshek, D. R., et al. (2012) · PLoS ONE · doi:10.1371/journal.pone.0044457 · Cited by 33
Self-citation
NovelUCHL1mutations reveal new insights into ubiquitin processing
Rydning, S. L., Backe, P. H., de Sousa, M. M. L., Iqbal, Z., Øye, A.-M., Sheng, Y., Yang, M., Lin, X., Slupphaug, G., Nordenmark, T. H., et al. (2016) · Human Molecular Genetics · doi:10.1093/hmg/ddw391 · Cited by 32
The Ubiquitination, Disaggregation and Proteasomal Degradation Machineries in Polyglutamine Disease
Nath, S. R., & Lieberman, A. P. (2017) · Frontiers in Molecular Neuroscience · doi:10.3389/fnmol.2017.00078 · Cited by 32
Endoplasmic reticulum quality control by garbage disposal
Kadowaki, H., & Nishitoh, H. (2018) · FEBS Journal · doi:10.1111/febs.14589 · Cited by 32
Pathways to healing: Plants with therapeutic potential for neurodegenerative diseases
Tyler, S. E. B., & Tyler, L. D. K. (2023) · IBRO Neuroscience Reports · doi:10.1016/j.ibneur.2023.01.006 · Cited by 33
Contribution of Apaf-1 to the pathogenesis of cancer and neurodegenerative diseases
Shakeri, R., Kheirollahi, A., & Davoodi, J. (2021) · Biochimie · doi:10.1016/j.biochi.2021.07.004 · Cited by 32
Oxidative Stress and Neurodegeneration: Interconnected Processes in PolyQ Diseases
Gkekas, I., Gioran, A., Boziki, M. K., Grigoriadis, N., Chondrogianni, N., & Petrakis, S. (2021) · Antioxidants · doi:10.3390/antiox10091450 · Cited by 31
Targeting Huntington’s disease through histone deacetylases
Gray, S. G. (2011) · Clinical Epigenetics · doi:10.1007/s13148-011-0025-7 · Cited by 32
Proteomics to study the diversity and dynamics of proteasome complexes: from fundamentals to the clinic
Bousquet, M., Fabre, B., Monsarrat, B., & Burlet‐Schiltz, O. (2011) · Expert Review of Proteomics · doi:10.1586/epr.11.41 · Cited by 33
Cytosolic aggregates perturb the degradation of nontranslocated secretory and membrane proteins
Chakrabarti, O., Rane, N. S., & Hegde, R. S. (2011) · Molecular Biology of the Cell · doi:10.1091/mbc.e10-07-0638 · Cited by 31
Natural genetic variation determines susceptibility to aggregation or toxicity in a C. elegansmodel for polyglutamine disease
Gidalevitz, T., Wang, N., Deravaj, T., Alexander-Floyd, J., & Morimoto, R. I. (2013) · BMC Biology · doi:10.1186/1741-7007-11-100 · Cited by 32
Proteasome subunit proteins and neuropathology in tauopathies and synucleinopathies: Consequences for proteomic analyses
Zouambia, M., Fischer, D. F., Hobo, B., de Vos, R. A. I., Hol, E. M., Varndell, I. M., Sheppard, P. W., & van Leeuwen, F. W. (2008) · PROTEOMICS · doi:10.1002/pmic.200700679 · Cited by 31
Could a Common Mechanism of Protein Degradation Impairment Underlie Many Neurodegenerative Diseases?
Smith, D. M. (2018) · Journal of Experimental Neuroscience · doi:10.1177/1179069518794675 · Cited by 32
Transgenic Animal Models of Huntington’s Disease
Yang, S., & Chan, A. W. S. (2011) · Current topics in behavioral neurosciences · doi:10.1007/7854_2010_105 · Cited by 29
Temporal Separation of Aggregation and Ubiquitination during Early Inclusion Formation in Transgenic Mice Carrying the Huntington’s Disease Mutation
Gong, B., Kielar, C., & Morton, A. J. (2012) · PLoS ONE · doi:10.1371/journal.pone.0041450 · Cited by 29
Baclofen, a GABAB receptor agonist, enhances ubiquitin-proteasome system functioning and neuronal survival in Huntington’s disease model mice
Kim, W., & Seo, H. (2013) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2013.12.034 · Cited by 29
Prions and the proteasome
Deriziotis, P., & Tabrizi, S. J. (2008) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2008.06.011 · Cited by 29
Proteomic Analysis of the Ubiquitin Landscape in the Drosophila Embryonic Nervous System and the Adult Photoreceptor Cells
Ramírez, J., Martinez, A., Lectez, B. L. P., Lee, S. Y., Franco, M., Barrio, R., Dittmar, G., & Mayor, U. (2015) · PLoS ONE · doi:10.1371/journal.pone.0139083 · Cited by 29
The effects of proteasome on baseline and methamphetamine-dependent dopamine transmission
Limanaqi, F., Biagioni, F., Busceti, C. L., Ryskalin, L., & Fornai, F. (2019) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2019.05.008 · Cited by 29
Modeling Polyglutamine Expansion Diseases with Induced Pluripotent Stem Cells
Naphade, S. B., Tshilenge, K., & Ellerby, L. (2019) · Neurotherapeutics · doi:10.1007/s13311-019-00810-8 · Cited by 30
Presynaptic dysfunction in Huntington's disease
Rozas, J. L., Gómez‐Sánchez, L., Tomás‐Zapico, C., Lucas, J. J., & Fernández‐Chacón, R. (2010) · Biochemical Society Transactions · doi:10.1042/bst0380488 · Cited by 29
Ubiquitinomics: History, methods, and applications in basic research and drug discovery
Steger, M., Karayel, Ö., & Demichev, V. (2022) · PROTEOMICS · doi:10.1002/pmic.202200074 · Cited by 30
Cytosolic stress granules relieve the ubiquitin‐proteasome system in the nuclear compartment
Xu, S., Gierisch, M. E., Schellhaus, A. K., Poser, I., Alberti, S., Salomons, F. A., & Dantuma, N. P. (2022) · The EMBO Journal · doi:10.15252/embj.2022111802 · Cited by 28
Is malfunction of the ubiquitin proteasome system the primary cause of α-synucleinopathies and other chronic human neurodegenerative disease?
Bedford, L., Hay, D., Paine, S., Rezvani, N., Mee, M., Lowe, J. S., & Mayer, R. J. (2008) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2008.10.009 · Cited by 29

Authors: Bennett, E. J., Shaler, T. A., Woodman, B., Ryu, K.-Y., Zaitseva, T. S., Becker, C. H., Bates, G. P., Schulman, H., & Kopito, R. R.
Affiliations: Stanford University (US)
King's College London (GB)
Corresponding author: Kopito, Ron R.
ORCID: Bennett, Eric J.
Ryu, Kwon-Yul
Zaitseva, Tatiana S.
Becker, Christopher H.
Bates, Gillian P.
Schulman, Howard
Kopito, Ron R.
Venue: Nature
Publisher: Springer Science and Business Media LLC
Published: 2007-08
Volume: 448
Issue: 7154
Pages: 704-708
ISSN: 0028-0836 (ISSN-L)
1476-4687
DOI: 10.1038/nature06022
OpenAlex: W2068275936
Semantic Scholar: 479d1eb636d3822cf616b0b9cf4afb67080aecda
Cited by: 497
References: 28
Citations by year: 2026: 2 · 2025: 11 · 2024: 10 · 2023: 10 · 2022: 10 · 2021: 17 · 2020: 11 · 2019: 26 · 2018: 20 · 2017: 25 · 2016: 19 · 2015: 25 · 2014: 38 · 2013: 26 · 2012: 38
FWCI: 17.80
Type: journal article
Language: en
Open access: closed
Licence: www.springer.com/tdm (tdm)
Locations: Nature (publishedVersion)
PubMed (publishedVersion)
RePEc: Research Papers in Economics (submittedVersion)
UCL Discovery (University College London) (submittedVersion)
Research Portal (King's College London) (submittedVersion)
Funders: Wellcome Trust
Topics: Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Genetic Neurodegenerative Diseases
Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Ubiquitin and proteasome pathways
Health Sciences › Medicine › Genetics (clinical) › Lysosomal Storage Disorders Research
Keywords: Huntington's disease, ubiquitin chains, ubiquitin-proteasome system, polyubiquitin, protein aggregation, huntingtin, neurodegeneration, proteasomal degradation, Alzheimer's disease, Parkinson's disease, CAG repeat expansion, brain proteomics
MeSH terms: Animals, Brain, Inclusion Bodies, Disease Models, Animal, Humans, Huntington Disease, Lysine, Mice, Transgenic, Ubiquitin, Polyubiquitin, Proteasome Endopeptidase Complex, Mice

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Global changes to the ubiquitin system in Huntington's disease

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Citations

Cites

Cited by

Related

Metadata

Record

About these checks